Motles E, Tetas M, Gonzalez M, Gomez A
Departamento de Ciencias Preclínicas Oriente, Facultad de Medicina, Universidad de Chile, Santiago.
Prog Neuropsychopharmacol Biol Psychiatry. 1994 May;18(3):585-602. doi: 10.1016/0278-5846(94)90015-9.
The aim of this work was to compare the behavioral effects of bromocriptine and quinpirole, two agonists of the D-2 dopaminergic receptor, either injected alone or combined with the D-1 dopaminergic receptor, SKF 38393. In ten adult mongrel cats the following experimental series were carried out: i) a dose-response study with bromocriptine administering 0.5-1.0-4.0 and 8.0 mg/kg s.c.; ii) a behavioral study injecting 4.0 mg/kg of bromocriptine plus 2.0 mg/kg of SKF 38393; iii) the same analysis administering 0.5 mg/kg of LY 171555 plus 1.0 mg/kg of SKF 38393, compared with the same dose of LY 171555 plus 4.0 mg/kg of SKF 38393; iv) an analysis of the behavioral effects of 8.0 mg/kg of bromocriptine compared with 1.0 mg/kg of quinpirole. The main findings were: i) bromocriptine injected, in four different doses evoked decrease in locomotion, and increase in indifference, inappetence, pupillary dilation and limb flicks; ii) the combined administration of 4.0 mg/kg of bromocriptine plus 2.0 mg/kg of SKF 38393 did not elicit behavioral changes different to those produced by bromocriptine alone; iii) quinpirole (1.0 mg/kg) evoked more intense behaviors than bromocriptine (8.0 mg/kg); iv) comparing quinpirole injected alone with the combination of quinpirole plus SKF 38393, this latter treatment produced more intense behaviors than the former. It is concluded: i) SKF 38393 potentiates the behavioral effects produced by quinpirole; this potentiation was not found when bromocriptine was combined with SKF 38393 and ii) the more intense behavioral effect elicited by quinpirole compared with bromocriptine may be explained by the fact that the latter drug is a selective D-2 agonist, whereas the former one is an agonist of the D-2 and the D-3 receptors.
本研究旨在比较两种D - 2多巴胺能受体激动剂溴隐亭和喹吡罗单独注射或与D - 1多巴胺能受体激动剂SKF 38393联合注射时的行为效应。对10只成年杂种猫进行了以下实验系列：i）溴隐亭剂量反应研究，皮下注射剂量分别为0.5、1.0、4.0和8.0 mg/kg；ii）行为学研究，注射4.0 mg/kg溴隐亭加2.0 mg/kg SKF 38393；iii）同样的分析，注射0.5 mg/kg LY 171555加1.0 mg/kg SKF 38393，并与相同剂量的LY 171555加4.0 mg/kg SKF 38393进行比较；iv）分析8.0 mg/kg溴隐亭与1.0 mg/kg喹吡罗的行为效应。主要发现如下：i）注射四种不同剂量的溴隐亭会导致运动减少，冷漠、食欲不振、瞳孔散大和肢体轻弹增加；ii）联合注射4.0 mg/kg溴隐亭加2.0 mg/kg SKF 38393未引起与单独注射溴隐亭不同的行为变化；iii）喹吡罗（1.0 mg/kg）引起的行为比溴隐亭（8.0 mg/kg）更强烈；iv）比较单独注射喹吡罗与喹吡罗加SKF 38393联合注射，后一种处理产生的行为比前一种更强烈。结论如下：i）SKF 38393增强了喹吡罗产生的行为效应；溴隐亭与SKF 38393联合使用时未发现这种增强作用；ii）与溴隐亭相比，喹吡罗引起更强烈的行为效应，这可能是因为后者是选择性D - 2激动剂，而前者是D - 2和D - 3受体的激动剂。
